Edwards Lifesciences Corporation's Stock Analysis

Edwards Lifesciences Increases Stock Incentive Program Shares by 7 Million

At the 2026 Annual Meeting, stockholders of Edwards Lifesciences Corporation approved the amendment of the Long-Term Stock Incentive Compensation Program, increasing the total number of shares available for issuance by 7 million to a new limit of 341.5 million shares. This change is part of the company's strategy to incentivize long-term performance among its executives.

During the same meeting, stockholders voted on several proposals, including the election of directors, approval of executive officer compensation, and the appointment of PricewaterhouseCoopers LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026. All proposals, including the amendment to the Long-Term Stock Program, received approval from the stockholders.

May 08, 2026 16:12:34

Edwards Lifesciences Appoints New CFO Theodora Mistras

Edwards Lifesciences has appointed Theodora Mistras as the Corporate Vice President and Chief Financial Officer, effective May 29, 2026. Mistras succeeds Scott B. Ullem, who has served in the role since 2014. She brings extensive experience from her previous positions at Viatris, Citigroup, and Goldman Sachs, where she focused on healthcare investment banking and corporate finance. Mistras holds degrees in international studies and economics from the University of Pennsylvania and the Wharton School.

As part of her compensation package, Mistras will receive an annual base salary of $925,000, a sign-on bonus of $2,013,000, and an award of restricted stock units valued at $8 million. These RSUs will vest over three years, contingent on her continued employment. Mistras will also be eligible for annual equity awards and severance benefits under the company's plans. The company has emphasized a smooth transition and continuity in leadership during this change.

May 04, 2026 16:53:21

Edwards Lifesciences Reports Strong Q1 Sales Growth and Guidance

Edwards Lifesciences announced its financial results for the first quarter of 2026, reporting a 16.7% increase in sales to $1.65 billion, with a notable 14.4% growth in Transcatheter Aortic Valve Replacement (TAVR) sales reaching $1.20 billion. The company has raised its full-year sales growth guidance to 9% to 11% and adjusted earnings per share (EPS) guidance to a range of $2.95 to $3.05, reflecting strong operational performance and ongoing strategic investments. TMTT sales also showed growth, totaling $173 million, supported by an expanding portfolio of therapies for mitral and tricuspid diseases.

In addition to the sales growth, Edwards reported a gross profit margin of 78.0% for the quarter, alongside a decrease in research and development expenses as a percentage of sales to 16.0%. The company continues to maintain a strong cash position with approximately $2.4 billion in cash and cash equivalents and entered a $500 million Accelerated Share Repurchase agreement. Edwards expects total sales for the second quarter of 2026 to be between $1.66 and $1.74 billion, with adjusted EPS projected between $0.70 and $0.76.

Apr 23, 2026 16:20:22

Edwards Lifesciences Reports Fourth Quarter and Full-Year 2025 Results

Edwards Lifesciences announced its financial results for the fourth quarter and full year ending December 31, 2025. The company reported a 13.3% increase in Q4 sales, reaching $1.57 billion, with Transcatheter Aortic Valve Replacement (TAVR) sales growing 12% to $1.16 billion. The total sales for FY 2025 grew by 11.5%, and the company has projected a sales growth of 8-10% for FY 2026. The adjusted earnings per share (EPS) for Q4 was reported at $0.58, while the company expects EPS for FY 2026 to be between $2.90 and $3.05.

In its TAVR segment, Edwards experienced consistent growth in both U.S. and international markets, supported by a strong body of clinical evidence and recent updates to treatment guidelines. The company also highlighted significant growth in its Transcatheter Mitral and Tricuspid Therapies (TMTT), with sales exceeding 40% in Q4. Edwards plans to expand its product offerings, including the recent FDA approval of SAPIEN M3 for mitral disease. The company concluded the year with approximately $3 billion in cash and $600 million in total debt, indicating a solid financial position as it moves into 2026.

Feb 10, 2026 16:22:48

Edwards Lifesciences Acquisition of JenaValve Blocked by Court

Edwards Lifesciences announced that the U.S. District Court for the District of Columbia has granted an injunction from the U.S. Federal Trade Commission, preventing the company from acquiring JenaValve Technology, Inc. Consequently, Edwards will not proceed with the acquisition, which the company believes would have benefited patients suffering from aortic regurgitation, a serious heart condition. The company expressed disagreement with the court's decision.

Following this development, Edwards Lifesciences has revised its full-year 2026 adjusted earnings per share guidance to a range of $2.90 to $3.05, up from the previous guidance of $2.80 to $2.95. The company remains focused on advancing its therapies for structural heart diseases and is actively enrolling patients in its JOURNEY pivotal trial for the SOJOURN transcatheter AR valve.

Jan 09, 2026 18:51:56

Edwards Lifesciences Announces CFO Transition Plan Effective Mid-2026

Scott Ullem, the Chief Financial Officer of Edwards Lifesciences, has announced his decision to transition from his role by mid-year 2026. The company is beginning the process of selecting a new CFO to ensure continuity and a smooth transfer of responsibilities. After the new CFO is appointed, Ullem will remain with the company in an advisory capacity.

This announcement was made public through a press release issued by the company on October 30, 2025. The transition plan is aimed at maintaining operational stability during the leadership change. Investors may want to monitor this transition closely, as changes in executive leadership can impact company performance and stock price.

Oct 30, 2025 16:29:32

Edwards Lifesciences Reports Q3 2025 Financial Results and Guidance

Edwards Lifesciences reported third quarter sales of $1.55 billion, reflecting a growth of 14.7% year-over-year. The sales growth was driven by a 12.4% increase in Transcatheter Aortic Valve Replacement (TAVR) sales and a notable 59.3% growth in Transcatheter Mitral and Tricuspid Therapies (TMTT), which generated $145.2 million. The company also reported an adjusted earnings per share (EPS) of $0.67, an increase from the previous year's quarter. Edwards has raised its full-year sales growth guidance to the high end of 9-10% and adjusted EPS guidance to a range of $2.56 to $2.62, indicating confidence in continued performance across its product lines.

The company’s TAVR sales growth was attributed to a renewed focus on treating patients with aortic stenosis, supported by new clinical guidelines that advocate for earlier intervention. Edwards’ TMTT portfolio, particularly the PASCAL and EVOQUE systems, has seen strong adoption globally. Additionally, the company is expanding its surgical portfolio with positive outcomes for its RESILIA therapies. Edwards ended the quarter with approximately $3 billion in cash and equivalents and announced an increase in its share repurchase authorization to $2.1 billion, reflecting a commitment to returning value to shareholders.

Oct 30, 2025 16:18:04

Edwards Lifesciences Announces $500 Million Share Repurchase Agreement

Edwards Lifesciences Corporation has entered into an accelerated share repurchase agreement to buy back $500 million of its common stock. This transaction will add to the more than $800 million in shares the company has repurchased in 2025. The initial delivery will consist of approximately 5 million shares, with the final number determined by the average share price during the agreement's term.

The share repurchase will be funded using the company's existing cash reserves. Following this agreement, Edwards Lifesciences has about $600 million remaining in its share repurchase authorization approved by its Board of Directors. This action may impact the company's stock price as it reflects a commitment to returning value to shareholders.

Aug 19, 2025 16:17:08

Edwards Lifesciences FTC Block Impacts Acquisition Plans and Guidance

Edwards Lifesciences announced that the U.S. Federal Trade Commission has moved to block its proposed acquisition of JenaValve Technology, which the company believes would enhance treatment options for patients with aortic regurgitation. Edwards disagrees with the FTC's decision and plans to continue pursuing regulatory approval, expecting a final determination by the end of the first quarter of 2026.

In light of the FTC's action, Edwards has revised its full-year 2025 financial guidance, maintaining its revenue guidance while increasing its adjusted Earnings Per Share (EPS) guidance to a range of $2.45-$2.55, up from $2.40-$2.50. The company indicated that there would be minimal impact on its third-quarter adjusted EPS guidance.

Aug 06, 2025 13:43:31

Executive Leadership Change at Edwards Lifesciences Announced

Larry L. Wood will resign from his role as Corporate Vice President and Group President, Transcatheter Aortic Valve Replacement and Surgical Structural Heart at Edwards Lifesciences, effective September 1, 2025. He is leaving to take a senior leadership position at another company outside of the cardiovascular sector.

Following Mr. Wood's departure, Daniel J. Lippis, currently the Corporate Vice President for Japan, Greater China, and Asia Pacific, will assume the role of Corporate Vice President responsible for Transcatheter Aortic Valve Replacement starting September 1, 2025.

Jul 24, 2025 18:22:54